Low Cross-Linked Silicic Acid in Polymer Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for producing silicic acid condensation products do not allow for controlled degradation in vivo applications, and they often result in materials with a high degree of cross-linking, which is not suitable for specific application forms like granulates, microparticles, fibers, or wound dressings.
Innovation Solution
The method involves controlling the condensation of silicic acid in aqueous or alcoholic solutions to form defined polyhedral structures with a low degree of cross-linking, preventing further condensation by mixing with a polymer, such as polyvinylpyrrolidone, to maintain these structures during processing and achieve a desired size range of 0.5 nm to 1000 nm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If silicic acid condensation is allowed to proceed to completion, then a high degree of cross-linking is achieved, but controlled degradation in vivo applications is prevented
Solution Approach 1:
The patent applies parameter changes by controlling the condensation process to achieve a specific, low degree of cross-linking (0-20%) rather than complete cross-linking. This is accomplished by adjusting condensation parameters such as pH, temperature, and catalyst concentration to stop the condensation reaction at an optimal point that enables controlled degradation while maintaining structural integrity for medical applications.
Solution Approach 2:
The patent employs preliminary action by incorporating polymers into the sol before condensation occurs. This preliminary mixing of polymer and silicic acid sol prevents excessive cross-linking from the outset, creating a matrix structure that allows controlled degradation to proceed in vivo while maintaining the necessary mechanical properties for medical device applications.
2Stability of the object's composition
If complete cross-linking of silicic acid is achieved, then structural stability is improved, but the material cannot be used for applications requiring controlled degradation
Solution Approach 1:
The patent changes the cross-linking parameter from complete to partial (0-20% cross-linking), achieving a balance where sufficient structural stability is maintained for device integrity while enough uncross-linked regions remain to enable controlled degradation in vivo. This parameter optimization allows the material to serve dual purposes: providing mechanical support and enabling biodegradation.
Solution Approach 2:
The patent creates a composite material system combining silicic acid condensates with polymers in a matrix structure. This composite approach allows the silicic acid component to provide controlled degradation while the polymer matrix maintains structural stability and mechanical properties, achieving both requirements simultaneously through material composition rather than单一 material properties.
3Reliability
If silicic acid structures are produced with a low degree of cross-linking, then controlled degradation is enabled, but the structures may be too small to provide sufficient mechanical support
Solution Approach 1:
The patent uses composite materials where silicic acid condensates (0.5-1000 nm) are embedded in a polymer matrix. This composite structure allows the nanoscale silicic acid structures to provide controlled degradation while the polymer matrix provides the necessary mechanical support and structural integrity. The synergistic combination enables both low cross-linking for degradation and sufficient strength for application.
Solution Approach 2:
The patent transitions from bulk-scale materials to nanoscale silicic acid structures (0.5-1000 nm) embedded in a polymer matrix. This dimensional change allows the material to achieve controlled degradation at the nanoscale while the macroscopic polymer matrix maintains mechanical strength. The nanoscale dimension of silicic acid structures enables higher surface area to volume ratio for degradation while the overall macrostructure provides mechanical support.
4Ease of manufacture
If existing condensation methods are used, then production is simplified, but the materials cannot be processed into desired application forms like granulates, microparticles, or fibers
Solution Approach 1:
The patent applies preliminary action by incorporating polymers into the sol before condensation and by controlling condensation to occur at specific stages. This preliminary preparation creates a processable matrix structure that can be formed into various application forms (granulates, microparticles, fibers, wound dressings) while maintaining controlled degradation properties. The polymer-silicic acid composite structure is prepared in advance for subsequent processing.
Solution Approach 2:
The patent uses parameter changes in the condensation process (pH, temperature, catalyst concentration, solvent composition) to control the size, shape, and distribution of silicic acid structures within the polymer matrix. By adjusting these parameters, the material can be processed into different application forms with specific characteristics while maintaining the low cross-linking degree necessary for controlled degradation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of silicic acid structures with a low degree of cross-linking, which can be used in medical applications, such as wound dressings and bone replacement materials, allowing for controlled degradation and enhanced interaction with biological tissues.
Implementation Method 1
controlling the condensation of silicic acid in aqueous or alcoholic solutions to form defined polyhedral structures
Implementation Method 2
preventing further condensation by mixing with a polymer
Data Source
AI summary
A material or biomaterial comprising silicic acid condensates having a low degree of cross-linking, and methods for its production are subject-matter of the invention. A method for the production of silicic acid structures having a low degree of cross-linking is disclosed, wherein a sol is produced, wherein further condensation is prevented when specific cross-linking of the silicic acid is reached, wherein, preferably, structures having a size of 0.5-1000 nm are produced, e.g. polyhedral structures or aggregates of the same. Further condensation can be prevented by means of mixing with a polymer. In one embodiment, this comprises nano-structured, silicon dioxide (SiO2) having a low degree of cross-linking that is embedded in a polymer matrix. The material can be used in medicine for therapeutic purposes, and can enter into direct contact with biological tissue of the body in this connection. This material herein enters into chemical, physical, and biological interactions with the corresponding biological systems. It can herein be decomposed, and can act as a supplier for the silicic acid required for metabolism. Furthermore, it can have a supportive or shielding effect. It can be present as a granulate, microparticles, fiber, and as a woven or nonwoven fabric produced therefrom, or as a layer on implants or wound dressings. The material can be used as a medical device or as a nutritional supplement.